Published 6 days ago • loading... • Updated 6 days ago

How to Avoid the Dreaded Rebound Effect After Leaving the Slimming Drugs

The irruption of drugs based on GLP-1 receptor agonists such as Ozempic, Saxenda or Wegovy has transformed the treatment of obesity and...

1 Articles

El Debate

Right

How to Avoid the Dreaded Rebound Effect After Leaving the Slimming Drugs

The irruption of drugs based on GLP-1 receptor agonists such as Ozempic, Saxenda or Wegovy has transformed the treatment of obesity and...

6 days ago·Madrid, Spain

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right1Center0Last Updated5 days agoBias Distribution

100% Right

Bias Distribution

100% of the sources lean Right

100% Right

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

El Debate broke the news in Madrid, Spain 6 days ago on Thursday, October 8, 2026.

Sources are mostly out of (0)

How to Avoid the Dreaded Rebound Effect After Leaving the Slimming Drugs

1 Articles

1 Articles

How to Avoid the Dreaded Rebound Effect After Leaving the Slimming Drugs

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Walmart to cover 250+ drugs free for employees starting 2027

Could GLP-1 drugs be anti-aging medications?

Agapidakis: Green Light for Obesity Drugs, Concerns 43,500 Beneficiaries, New "I Prevent" Cycle for Breast Cancer

Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial

One Suspected Case of Vision Impairment Following GLP-1 Administration in Korea

Losing Weight without a Syringe: What the New Wegovy Pill Can and What It Costs

Similar News Topics

Similar News Topics

More stories like this

Walmart to cover 250+ drugs free for employees starting 2027

Could GLP-1 drugs be anti-aging medications?

Agapidakis: Green Light for Obesity Drugs, Concerns 43,500 Beneficiaries, New "I Prevent" Cycle for Breast Cancer

Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial

One Suspected Case of Vision Impairment Following GLP-1 Administration in Korea

Losing Weight without a Syringe: What the New Wegovy Pill Can and What It Costs

How to Avoid the Dreaded Rebound Effect After Leaving the Slimming Drugs

1 Articles

1 Articles

Translate IconHow to Avoid the Dreaded Rebound Effect After Leaving the Slimming Drugs

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Walmart to cover 250+ drugs free for employees starting 2027

Could GLP-1 drugs be anti-aging medications?

Agapidakis: Green Light for Obesity Drugs, Concerns 43,500 Beneficiaries, New "I Prevent" Cycle for Breast Cancer

Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial

One Suspected Case of Vision Impairment Following GLP-1 Administration in Korea

Losing Weight without a Syringe: What the New Wegovy Pill Can and What It Costs

Similar News Topics

Similar News Topics

More stories like this

Walmart to cover 250+ drugs free for employees starting 2027

Could GLP-1 drugs be anti-aging medications?

Agapidakis: Green Light for Obesity Drugs, Concerns 43,500 Beneficiaries, New "I Prevent" Cycle for Breast Cancer

Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial

One Suspected Case of Vision Impairment Following GLP-1 Administration in Korea

Losing Weight without a Syringe: What the New Wegovy Pill Can and What It Costs

How to Avoid the Dreaded Rebound Effect After Leaving the Slimming Drugs

Bias Distribution

Factuality